The Oncobiome consortium reunited during the AACR Annual Meeting 2025. Prof Laurence Zitvogel chaired the session “The Microbiota and Cancer Prevention, Diagnosis, and Treatment” while eight members of the consortium presented their latest results:
- “Optimizing microbiome modulation to enhance cancer immunotherapy efficacy” B. Routy
- “Gut dysbiosis: a risk factor for cancer patients” L. Zitvogel
- “The human microbiome as a diagnostic and treatment-supporting target in oncology” N.Segata
- “Profiling microRNAs in fecal immunochemical test leftover buffer to improve colorectal cancer screening.” A. Naccarati
- “Microbiome profiling reveals that fecal microbiota transplantation (FMT) modulates response and toxicity when combined with immunotherapy in patients with lung cancer and melanoma (FMT-LUMINate NCT04951583)” S. Duttagupta
- “Microbiome alterations of colorectal cancer according to age of onset, stage, anatomic location, and mismatch repair deficiency” G. Piccinno
- “Desaminotyrosine contributes to the anticancer effect of fecal microbial transplantation during immune checkpoint blockade in mice and patients” S. Thomas
- “Multipronged approach identifying new hallmarks of antibiotics-mediated immunosuppression in a prospective trial of cancer immunotherapy” C. Alves Costa Silva
-
